Method of isolating and purifying sICAM-1
AssigneeBayer Aktiengesellschaft
InventorsAlan McClelland, Jeffrey M. Greve
Life of this patent
Estimating the term…
Abstract
The present invention relates to a soluble form of-intercellular adhesion molecule (sICAM-1) and purified and isolated human sICAM-1. This invention also relates to a purified and isolated DNA sequence encoding sICAM-1. The extracellular domain of sICAM-1 and insoluble ICAM-1 are substantially the same. ICAM-1 is involved in the process through which lymphocytes attach to cellular substrates during inflammation and serves as the major human rhinovirus receptor (HRR). sICAM-1 therefore has both the property of reducing immune inflammation and inhibiting infection of rhinovirus and Coxsackie A virus.
Claims6
A method of recovering soluble intercellular adhesion molecule-1 (sICAM-1, having the amino acid sequence set forth in FIG. 1) in substantially pure form comprising the steps of:
- (A) removing the supernatant from unlysed cells,
- (B) introducing the supernatant to an affinity matrix containing immobilized antibody which binds to sICAM-1,
- (C) permitting said sICAM-1 to bind to said antibody of said matrix,
- (D) washing said affinity matrix to remove unbound contaminants, and
- (E) recovering said sICAM-1 in substantially pure form by eluting said sICAM-1 from said matrix.
Dependencies are inferred from the claim text.